Plain-English translation of NCT05255653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is actually four linked trials testing whether personalizing endometrial cancer treatment based on your tumor's genetic makeup works better than standard treatment. Depending on your tumor's genetic profile, you may receive different combinations of radiation, , , , or hormone therapy — or in some cases, no additional treatment after surgery. The goal is to give you exactly what you need without unnecessary side effects.
Endometrial cancer is not one-size-fits-all: different tumors have different genetic mutations that respond differently to treatment. This trial tests whether matching treatment to your specific tumor's genetics can help more patients survive longer and better, while reducing harsh side effects from unnecessary drugs.
You likely qualify if…
You likely don't qualify if…
After surgery, you'll be assigned to one of four treatment groups based on your tumor's genetic profile. Some participants receive radiation combined with and then a medication like or for up to a year; others receive radiation followed by hormone pills for two years; and some with very early-stage cancers may receive no additional treatment at all. You'll have regular clinic visits for treatment, blood tests, and imaging scans to monitor your progress and watch for side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Canada
France
Netherlands